menu
    • menu

    Company profile for Editas Medicine

    NEW Drugs in Dev: 9
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases. At Editas Medicine, we believe we have entered a new era in genomic medicine as the growth of genomic information in recent years has significantly expanded our understanding of genetically defined diseases. Furthermore, a new technology known as CRISPR (Clustered Regularly Interspaced Short Palindro...
    Editas Medicine is building the leading genome editing company dedicated to treating patients with genetically defined diseases. At Editas Medicine, we believe we have entered a new era in genomic medicine as the growth of genomic information in recent years has significantly expanded our understanding of genetically defined diseases. Furthermore, a new technology known as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has the potential to achieve accurate, directed changes in DNA and fulfill the promise that started with the sequencing of the human genome – the potential to treat diseases at their source.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Editas MedicineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11 Hurley Street Cambridge, MA 02141
    Telephone
    Telephone
    617.401.9000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.editasmedicine.com/company-overview/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/editas-medicine
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Editas Medicine Reveals Q1 2026 Results And Business Updates
    Editas Medicine Reveals Q1 2026 Results And Business Updates

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287494/0/en/editas-medicine-announces-first-quarter-2026-results-and-business-updates.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Editas Medicine Showcases EDIT-401 Progress For Hyperlipidemia
    Editas Medicine Showcases EDIT-401 Progress For Hyperlipidemia

    27 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7211526

    FIRSTWORD PHARMA
    27 Apr 2026
    Share Share
    Editas Medicine Confirms Uspto Backs Broad Institute
    Editas Medicine Confirms Uspto Backs Broad Institute

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263679/0/en/Editas-Medicine-Announces-U-S-Patent-and-Trademark-Office-Reaffirms-its-Prior-Decision-in-Favor-of-the-Broad-Institute-in-CRISPR-Cas9-Interference.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    Editas Medicine Reports Q4, FY 2025 Results and Update
    Editas Medicine Reports Q4, FY 2025 Results and Update

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251669/0/en/Editas-Medicine-Announces-Fourth-Quarter-and-Full-Year-2025-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Editas Medicine To Participate In Upcoming Investor Conferences
    Editas Medicine To Participate In Upcoming Investor Conferences

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242678/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Editas Medicine Unveils EDIT-401 Poster at AHA Scientific Meet
    Editas Medicine Unveils EDIT-401 Poster at AHA Scientific Meet

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179375/0/en/Editas-Medicine-Announces-EDIT-401-Poster-Presentation-at-the-American-Heart-Association-AHA-Scientific-Sessions-2025.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search